Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The lipid accumulation product is a powerful tool to predict metabolic syndrome in undiagnosed Brazilian adults

Full text
Author(s):
Nascimento-Ferreira, Marcus Vinicius [1, 2, 3] ; Rendo-Urteaga, Tara [1, 2] ; Vilanova-Campelo, Regina Celia [4, 1, 3] ; Carvalho, Heraclito Barbosa [1] ; Oliveira, Germano da Paz [5] ; Paes Landim, Mauricio Batista [4, 5] ; Torres-Leal, Francisco Leonardo [3]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Sch Med, Youth Child Cardiovasc Risk & Environm YCARE Res, Sao Paulo - Brazil
[2] Univ Zaragoza, Growth Exercise Nutr & Dev GENUD Res Grp, Fac Hlth Sci, IA2, IIS Aragon, Ctr Invest Biomed Red Fisiopatol O, Zaragoza - Spain
[3] Univ Fed Piaui, Metab Dis Exercise & Nutr DOMEN Res Grp, Teresina - Brazil
[4] Univ Fed Piaui, Hlth Sci Ctr, Teresina - Brazil
[5] Univ Fed Piaui, Univ Hosp, Teresina - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Clinical Nutrition; v. 36, n. 6, p. 1693-1700, DEC 2017.
Web of Science Citations: 10
Abstract

Background \& aims: Lipid accumulation product (LAP) is emergent predictor of central lipid accumulation linked to diabetes risk and cardiovascular disease. In this study, our aims were (i) to assess the accuracy of the LAP for predicting metabolic syndrome (MS) in subjects without diagnosis of cardiovascular disease (CVD) and type 2 diabetes mellitus compared with other classical anthropometric parameters and (ii) to estimate the optimal LAP cut-off point to predict MS in this population. Subjects/Methods: We conducted a cross-sectional study with representative undiagnosed subjects aged 20-79 years (n = 201; 37.8% men), selected by Simple random sampling. In this study, subjects without previous diagnosis of CVD and type 2 diabetes mellitus, and those who did not make use of continuous medication were included. The independent variables were body mass index (BMI), waist circumference (WC), waist-to-height ratio (WHtR) and waist-to-hip ratio (WHR) and LAP. MS was defined by American Heart Association and the National Heart, Lung, and Blood Institute (AHA/NHLBI); International Diabetes Federation (IDF); and a harmonized criteria between AHA/NHLBI and IDF. Results: The prevalence of MS was 78.9% and 69.6% for men and women, respectively. LAP showed better area under the curve (AUC) for MS in three different criteria than those indexes based on body mass index, waist circumference, waist-to-height ratio and waist-to-hip ratio, even after adjusting for age and sex. In the harmonized criteria, the cut-off point of 34.2 cm.mmol/L for LAP showed the highest accuracy for MS (sensitivity 0.90, specificity 0.61, positive likelihood ratio of 2.31 and negative likelihood ratio of 0.17). Conclusions: LAP is a simple and accurate predictor tool for MS in undiagnosed adults. Moreover, it has significantly higher predictability than other screening tools commonly used to find subjects at risk of CVD and type 2 diabetes mellitus development, with the best performance at the 34.2 cm.mmol/L cut-off point. (C) 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. (AU)

FAPESP's process: 14/25233-0 - Development and validation of methods to assess dietary intake and body composition in a multicenter study: SAYCARE study
Grantee:Tara Rendo Urteaga
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 14/11468-6 - Design and implementation of the SAYCARE Study: South American Youth/Child Cardiovascular and Environmental Study
Grantee:Heraclito Barbosa de Carvalho
Support type: Regular Research Grants